These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects. Gootz TD; Brighty KE Med Res Rev; 1996 Sep; 16(5):433-86. PubMed ID: 8865150 [No Abstract] [Full Text] [Related]
5. In vitro activity of E-3846, a new fluoroquinolone, against gram-negative and gram-positive bacteria. Moros M; Coll R; Esteve M; Parés J; Xicota MA Chemioterapia; 1987 Jun; 6(2 Suppl):149-51. PubMed ID: 3509373 [No Abstract] [Full Text] [Related]
8. [Pharmacokinetics of trovafloxacin: its clinical significance]. Clara LO; Biglia MA Medicina (B Aires); 1999; 59 Suppl 1():17-22. PubMed ID: 10436550 [TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone. Park HS; Kim HJ; Seol MJ; Choi DR; Choi EC; Kwak JH Antimicrob Agents Chemother; 2006 Jun; 50(6):2261-4. PubMed ID: 16723601 [TBL] [Abstract][Full Text] [Related]
10. [Antimicrobial activity and action mechanism of ofloxacin]. Padeĭskaia EN Antibiot Khimioter; 1996; 41(9):13-23. PubMed ID: 9005780 [No Abstract] [Full Text] [Related]
11. In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone. Fujikawa K; Chiba M; Tanaka M; Sato K Antimicrob Agents Chemother; 2005 Jul; 49(7):3040-5. PubMed ID: 15980395 [TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates. Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230 [TBL] [Abstract][Full Text] [Related]
13. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates. Barry AL; Fuchs PC; Brown SD Antimicrob Agents Chemother; 2001 Jun; 45(6):1923-7. PubMed ID: 11353655 [TBL] [Abstract][Full Text] [Related]
14. Gaps and perspectives of new fluoroquinolones. Neuman M; Esanu A Drugs Exp Clin Res; 1988; 14(6):385-91. PubMed ID: 3215107 [TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of quinolones. Dalhoff A Drugs; 1995; 49 Suppl 2():197-9. PubMed ID: 8549302 [No Abstract] [Full Text] [Related]
16. Antimicrobial activity, pharmacokinetics and clinical studies of balofloxacin (Q-35) in obstetrics and gynaecology. Cho N; Miyakawa Z; Kimura T; Shimizu A; Notake Y; Kunii K Drugs; 1995; 49 Suppl 2():391-2. PubMed ID: 8549373 [No Abstract] [Full Text] [Related]
17. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan. Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and antimicrobial activity of 1,3,4-triaryl-2-azetidinones. Diurno MV; Mazzoni O; Piscopo E; Bolognese A Farmaco; 1992 Feb; 47(2):239-47. PubMed ID: 1510796 [TBL] [Abstract][Full Text] [Related]
19. [In vitro evaluation of lomefloxacin]. Dette GA; Knothe H Arzneimittelforschung; 1989 Aug; 39(8):832-5. PubMed ID: 2818672 [TBL] [Abstract][Full Text] [Related]